ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

ACAD 38.36 -0.54 (-1.39%)
price chart
Stock Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. to Present at the ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the ...
ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare ...  MarketWatch
Trending Stocks: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Yelp Inc ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) belongs to Healthcare sector. Its weekly performance is 0.87%. On last trading day company shares ended up $38.36.
ACADIA Pharmaceuticals Lifted to Buy at Vetr Inc. (ACAD)
Finally, analysts at Needham & Company LLC lowered their price target on shares of ACADIA Pharmaceuticals from $40.00 to $38.00 and set a buy rating on the stock in a research note on Thursday, March 12th.
Lifshitz & Miller Law Firm Announces Investigation of Acadia Pharmaceuticals ...
Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board of Acadia Pharmaceuticals Inc. (ACAD). Specifically, on March 11, 2015, ACAD delayed the submission of a U.S. application to market its lead drug ...
Hagens Berman Reminds ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD ...
SAN FRANCISCO, Apr. 07, 2015 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors with losses exceeding $100,000 of the May 12, 2015 lead plaintiff deadline in a class action lawsuit filed ...
Hagens Berman Reminds ACADIA Pharmaceuticals, Inc. ACAD Investors With ...
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors with losses exceeding $100,000 of the May 12, 2015 lead plaintiff deadline in a class action lawsuit filed against ACADIA Pharmaceuticals, Inc. ACAD, -1.66 ...
ACADIA Pharmaceuticals Receives Consensus Rating of "Buy" from ...  WKRB News
Stocks under Bearish Claws - Wisconsin Energy (WEC) Capstone Turbine ...  Techsonian (press release)
Should AbbVie, Inc. Buy Acadia Pharmaceuticals to Help Fight Parkinson's ...
Perhaps as a direct consequence of these issues, we witnessed the company's longtime CEO Uli Hacksell abruptly retire last month, even relinquishing his seat on the Board.
Technical Report on ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) (TREND ANALYSIS) shares were traded with a significant increase in volume. The stock closed last trading session at $37.53, up by 6.89%, with a volume of 3,398,819 shares against an average volume for the ...
Vetr Inc. Downgrades ACADIA Pharmaceuticals to Hold (ACAD)  Mideast Time
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia ...
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of California.
Acadia Will Outperform, Worth $48/Share Says Leerink
In a report published Thursday, Leerink analysts initiated coverage of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with an Outperform rating and a price target of $48.